A5101684236- Renal cell carcinoma treatment
- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Renal and related cancers
- Urinary and Genital Oncology Studies
- Cancer, Lipids, and Metabolism
- Clusterin in disease pathology
- Cancer Immunotherapy and Biomarkers
- Urologic and reproductive health conditions
- Urological Disorders and Treatments
- Urinary Bladder and Prostate Research
- Cancer Genomics and Diagnostics
- Testicular diseases and treatments
- Ferroptosis and cancer prognosis
- Pelvic floor disorders treatments
- Multiple and Secondary Primary Cancers
- Radiopharmaceutical Chemistry and Applications
- Pancreatic and Hepatic Oncology Research
- Renal and Vascular Pathologies
- Hormonal and reproductive studies
- Economic and Financial Impacts of Cancer
- Cancer, Hypoxia, and Metabolism
- Cancer Diagnosis and Treatment
- Urinary Tract Infections Management
Kobe University
2012-2025
Hamamatsu University School of Medicine
2012-2024
Hamamatsu University Hospital
2022-2024
Gifu University
2023
Hamamatsu University
2018-2023
Weatherford College
2021
University Hospital Olomouc
2019
Pfizer (Germany)
2019
Palacký University Olomouc
2019
Fujitsu (Japan)
2008-2017
The ATLAS trial compared axitinib versus placebo in patients with locoregional renal cell carcinoma (RCC) at risk of recurrence after nephrectomy.In a phase III, randomized, double-blind trial, had >50% clear-cell RCC, undergone nephrectomy, and no evidence macroscopic residual or metastatic disease [independent review committee (IRC) confirmed]. intent-to-treat population included all randomized [≥pT2 and/or N+, any Fuhrman grade (FG), Eastern Cooperative Oncology Group status 0/1]....
Large meta-analyses have documented that maximum androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer confers survival benefits, although it remains controversial. Also, we and others reported the effectiveness of second line hormonal therapy relapses after initial hormone therapy. However, there is little clinical evidence latter treatment strategy. Therefore, in this multicenter trial Japan analyzed outcomes following alternative changing from 1 antiandrogen to...
Introduction: Innovation of robotic surgery is still actively growing, and various novel systems are in the process development. The objective this study was to assess perioperative outcomes robot-assisted partial nephrectomy (RAPN) using hinotori surgical robot system, a recently developed platform, for patients with small renal tumors. Methods: This prospectively included total 30 consecutive who were found have tumors subsequently underwent RAPN between April November 2022. Major these...
The hinotori surgical robot system, a newly launched platform, has already been utilized in several urological robotic surgeries; however, limited information is available terms of its feasibility and safety each type surgery. objectives this study were to describe the perioperative outcomes first series six patients who underwent robot-assisted adrenalectomy (RAA) using hinotori, compare with similar set five undergoing RAA existing da Vinci.This included total 11 consecutive adrenal tumors...
Abstract In the field of urology, robotic surgery has gained rapid and wide acceptance as a standard surgical approach in majority major surgeries over last decade. To date, da Vinci system been dominant platform surgery; however, several newly developed systems have recently introduced routine clinical practice. Of these, hinotori, first made-in-Japan system, is characterized by various unique attractive features different from existing use this gradually increased mainly urologic cancer...
None declared.
Abstract Background This study aimed to investigate the association between Fc-gamma receptor IIIA (FCGR3A) 158 polymorphism and clinical outcomes in kidney transplantation (KTx) patients. Specifically, we focused on late-onset neutropenia (LON) ABO-incompatible (ABOi) or HLA-incompatible (HLAi) KTx recipients who underwent rituximab (RTx) desensitization therapy. Methods FCGR3A 158F/V polymorphisms were identified 85 ABOi HLAi RTx at our institution April 2008 October 2021. We analyzed...
Several investigators have revealed that urokinase-type plasminogen activator (uPA) and its receptor (uPAR) are overexpressed in serum as well tumor tissues patients with various types of cancer. In this study, we examined whether the levels uPA uPAR could be used predictors progression prognosis prostate cancer.Serum 54 healthy controls, 62 benign prostatic hypertrophy (BPH), 72 cancer were measured by a sandwich enzyme immunoassay.The mean significantly higher than those controls BPH....
In the phase III JAVELIN Renal 101 trial, first-line avelumab plus axitinib demonstrated a progression-free survival (PFS) and objective response rate (ORR) benefit versus sunitinib in patients with advanced renal cell carcinoma (aRCC). However, efficacy elderly remains unclear. We report safety by age group from second interim analysis of overall (OS).PFS ORR as per blinded independent central review (RECIST 1.1), OS, were assessed patient groups aged <65, ≥65 to <75, ≥75 years.In arms,...
The aims of the present study were to describe perioperative findings first series patients undergoing robot-assisted radical nephrectomy (RARN) with a newly launched platform, hinotori surgical robot system, and compare similar set receiving RARN existing da Vinci.This included 34 patients, consisting 13 21 using Vinci robotic systems, respectively. As rule, was performed via an intraperitoneal approach employing 3 arms, irrespective systems.In group, median age, body mass index tumor...
This study aimed to assess the prognostic outcomes in mRCC patients receiving second-line TKI following first-line IO combination therapy.
BACKGROUND: Renal cell cancer (RCC) is a chemoresistant disease with no active chemotherapeutic agent achieving objective response rates higher than 15%. Clusterin survival gene that increases in human renal tubular epithelial cells after various states of injury and disease. Downregulation clusterin, using antisense oligonucleotides (ASO), has recently been shown to increase chemosensitivity several prostate models. The objectives this study were evaluate clusterin expression levels RCC...
GRP78 induction has recently been shown to play a critical role in maintaining cell viability against several kinds of stress, including depletion endoplasmic reticulum Ca2+ and accumulation unglycosylated proteins, under specific experimental conditions. However, the functional significance after stressful treatment not well defined. This article characterizes different biological features associated with by two stress agents, calcium ionophore, ionomycin (IM), glycosylation inhibitor,...